Replies to post #17839 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

…please explain how MNTA could have done better at preventing TEVA from switching…patients [to] 40mg [Copaxone]?

MNTA’s management was fooled by TEVA’s public statements in 2012 that 40mg Copaxone might achieve, at most, 25% of the US Copaxone market. In retrospect, we can see that TEVA early statements about the potential market share of 40mg Copaxone were misdirection and that TEVA intended to switch a much larger proportion of the US market from 20mg to 40mg.

p.s. It’s hard for me to blame MNTA’s management unduly insofar as I too thought TEVA would have more limited success with the 40mg product.